NeuroSense Therapeutics Ltd. develops therapies for severe neurodegenerative diseases, led by PrimeC, a proprietary fixed-dose oral extended-release combination of ciprofloxacin and celecoxib. Company news centers on PrimeC clinical and biomarker data in amyotrophic lateral sclerosis, Alzheimer’s disease program updates, regulatory interactions, and scientific publications or conference presentations related to the PARADIGM and PARAGON programs.
Recurring developments also include intellectual-property coverage for the PrimeC composition, including patent grants in Brazil, the United States and Australia, as well as Nasdaq listing compliance notices, shareholder voting matters, capital-structure disclosures, governance updates, material agreements, and operating or financial results.
NeuroSense Therapeutics (Nasdaq: NRSN) provides a business update for Q1 2024, highlighting key collaborations and positive results from the PARADIGM Study in ALS and Alzheimer's disease. The company is focused on advancing its treatments for neurodegenerative diseases, with plans for further research and clinical trials in the coming months.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.